6 Results

People

  1. Rathkopf
    Rathkopf
  2. Lefkowitz
    Lefkowitz
  3. Scher
    Scher
  4. Schwartz
    Schwartz
  5. Shah
    Shah
  6. Tse
    Tse
  7. Anand
    Anand
  8. Cane
    Cane
  9. Carvajal
    Carvajal
  10. Danila
    Danila

Groups

  1. Department of Medicine (6)
  2. Genitourinary Oncology Service (6)
  3. Solid Tumor Oncology Division (6)
  4. Radiology, Department of (3)
  5. Biostatistics Service (2)
  6. Body Imaging Service (2)
  7. Center for Pancreatic Cancer Research (2)
  8. Epidemiology and Biostatistics (2)
  9. Advanced Practice Providers (1)
  10. Breast Medicine Service (1)
  1. "anemia"
  2. "Dana Rathkopf"
Formats
  1. Journal Article (6)
Groups
  1. Department of Medicine (6)
  2. Genitourinary Oncology Service (6)
  3. Solid Tumor Oncology Division (6)
  4. Radiology, Department of (3)
  5. Biostatistics Service (2)
  6. Body Imaging Service (2)

More Groups

People
  1. Dana Rathkopf (6)
  2. Archie Tse (2)
  3. Gary Schwartz (2)
  4. Howard Scher (2)
  5. Manish Shah (2)
  6. Robert Lefkowitz (2)

More People

Years
  1. 2022 (1)
  2. 2015 (1)
  3. 2013 (1)
  4. 2010 (2)
  5. 2007 (1)
Publications
  1. Cancer Chemotherapy and Pharmacology (2)
  2. Clinical Cancer Research (2)
  3. European Journal of Cancer (1)
  4. Lancet (1)
Publishers
  1. American Association for Cancer Research (2)
  2. Springer (2)
  3. Elsevier Inc. (1)
  4. Elsevier Science, Inc. (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study investigating AZD8186, a potent and selective inhibitor of PI3Kβ/δ, in patients with advanced solid tumors
    Journal Article

    Choudhury, A. D.; Higano, C. S.; de Bono, J. S.; Cook, N.; Rathkopf, D. E.; Wisinski, K. B.; Martin-Liberal, J.; Linch, M.; Heath, E. I.; Baird, R. D.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer
    Journal Article

    Hussain, M.; Rathkopf, D.; Liu, G.; Armstrong, A.; Kelly, W. K.; Ferrari, A.; Hainsworth, J.; Joshi, A.; Hozak, R. R.; Yang, L.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
    Journal Article

    Rathkopf, D. E.; Picus, J.; Hussain, A.; Ellard, S.; Chi, K. N.; Nydam, T.; Allen-Freda, E.; Mishra, K. K.; Porro, M. G.; Scher, H. I.; more...
    Cancer Chemotherapy and Pharmacology (2013)

    Fulltext@MSK | Save
  • Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
    Journal Article

    Scher, H. I.; Anand, A.; Rathkopf, D.; Shelkey, J.; Morris, M. J.; Danila, D. C.; Larson, S.; Humm, J.; Fleisher, M.; Sawyers, C. L.; more...
    Lancet (2010)

    Fulltext@MSK | Save
  • A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
    Journal Article

    Dickson, M. A.; Shah, M. A.; Rathkopf, D.; Tse, A.; Carvajal, R. D.; Wu, N.; Lefkowitz, R. A.; Gonen, M.; Cane, L. M.; Dials, H. J.; more...
    Cancer Chemotherapy and Pharmacology (2010)

    Fulltext@MSK | Save
  • Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors
    Journal Article

    Fornier, M. N.; Rathkopf, D.; Shah, M.; Patil, S.; O'reilly, E.; Tse, A. N.; Hudis, C.; Lefkowitz, R.; Kelsen, D. P.; Schwartz, G. K.
    Clinical Cancer Research (2007)

    Fulltext@MSK | Save